The Eighth Annual Round It Up for Lymphoma Campaign Raises Critical Funds for the Lymphoma Research Foundation and The University of Chicago Medicine Biobank
Due to an increase in new and effective treatments, outcomes among lymphoma patients have improved, with a 10-year survival rate reported to be higher than 50 percent for many subtypes. With more patients living with and after a lymphoma diagnosis,…
In our increasingly interconnected world, people are using social media to support nonprofits—how can you make the biggest impact? When the first-ever telethon was hosted in 1949, the idea of pledging charitable donations over the phone was new but caught…
The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with nearly 70 LRF-affiliated scientists presenting more than 100 abstracts at this year’s conference.
Playing the long game is not a new concept for Lymphoma Research Foundation Grantee and Scientific Advisory Board (SAB) member Ari Melnick, MD, of NewYork-Presbyterian/Weill Cornell Medicine. Lymphoma research is not a field for those looking for instant gratification, but Dr. Melnick has never taken a sprinter’s approach to finding cures for lymphoma. He is more of a marathoner.
Understanding Cancer-Related Financial Toxicity Cancer is one of the costliest conditions to treat today in the United States. With outcomes among patients with lymphoma improving, managing costs related to the diagnosis and treatment of their disease is a major concern.…
The Lymphoma Research Foundation is proud to launch its new flagship publication, Pulse. Published quarterly, Pulse provides the latest updates on the Foundation and its focus on lymphoma and chronic lymphocytic leukemia (CLL) research, awareness and education. Pulse will also…
Jeff Block and Steven Eichberg Joins Lymphoma Research Foundation Board of Directors
On November 2, 2019, the Lymphoma Research Foundation sent a letter to Donald Thompson, Director, Division of Acute Care at the Centers for Medicare and Medicaid Services requesting for MS-DRG reclassification for certain cases involving the use of chimeric antigen receptor T-cell (CAR T-cell) therapies.
This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).
